drugset / Trial / NCT01623375
A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the absolute bioavailability of insulin degludec (IDeg) in healthy subjects.
Timeline
- Start
- 2012-06
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin degludec | Protein / enzyme biologic | 0.04 iu/kg | Subcutaneous |
| Subject | insulin degludec | Protein / enzyme biologic | 0.4 iu/kg | Subcutaneous |